Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study

Table 3 Baseline clinical characteristics of antiretroviral-naïve HIV+ patients initiating atazanavir-containing vs. atazanavir-free regimens

	Commercial Database					Medicaid Database
	ATV-Containing Regimen N = 2,437		ATV-Free Regimen N = 19,774		p-value	ATV-Containing Regimen N = 1,505		ATV-Free Regimen N = 5,631		p-value
	N	%	N	%		N	%	N	%
CHADS₂ Score^a
0	2,040	83.7 %	16,382	82.8 %	0.3593	1,019	67.7 %	3,745	66.5 %	0.6718
1	321	13.2 %	2,734	13.8 %		330	21.9 %	1,294	23.0 %
2	67	2.7 %	535	2.7 %		113	7.5 %	448	8.0 %
3–6	9	0.4 %	123	0.6 %		43	2.9 %	144	2.6 %
Diabetes Mellitus^b	115	4.7 %	961	4.9 %	0.7597	137	9.1 %	563	10.0 %	0.2996
Hypertension^b	370	15.2 %	3,256	16.5 %	0.1058	450	29.9 %	1,733	30.8 %	0.5125
Dyslipidemia^b	306	12.6 %	2,473	12.5 %	0.9438	158	10.5 %	576	10.2 %	0.7600
Renal Disease	107	4.4 %	640	3.2 %	0.0029	146	9.7 %	524	9.3 %	0.6404
Tobacco Use Disorder	110	4.5 %	986	5.0 %	0.3095	347	23.1 %	1,257	22.3 %	0.5448
COPD	37	1.5 %	279	1.4 %	0.6730	88	5.8 %	392	7.0 %	0.1253
Anemia	186	7.6 %	1,710	8.6 %	0.0905	283	18.8 %	1,088	19.3 %	0.6507
Hepatitis C	67	2.7 %	419	2.1 %	0.0448	173	11.5 %	595	10.6 %	0.3018
Alcohol Abuse Disorder	14	0.6 %	147	0.7 %	0.3536	90	6.0 %	246	4.4 %	0.0088
Drug Abuse Disorder	137	5.6 %	1,250	6.3 %	0.1780	488	32.4 %	1,666	29.6 %	0.0331
Autoimmune/Inflammatory Disorders	86	3.5 %	731	3.7 %	0.6779	80	5.3 %	284	5.0 %	0.6700
Circulatory Disease	504	20.7 %	4,470	22.6 %	0.0316	570	37.9 %	2,178	38.7 %	0.5686
Oral Contraceptives	25	1.0 %	146	0.7 %	0.1255	13	0.9 %	42	0.7 %	0.6422

COPD chronic obstructive pulmonary disorder, ATV atazanavir, SD standard deviation
^aCHADS₂ is based on the presence of diagnoses of congestive heart failure, hypertension, diabetes, and stroke or transient ischemic attack and age ≥ 75 [11, 12]; ^bBoth diagnoses and medication use were evaluated

ISSN: 1471-2334